A phase II study of weekly paclitaxel/estramustine/carboplatin in hormone-refractory prostate cancer

Clinical Genitourinary Cancer

Volumn 5, Issue 2, 2006, Pages 131-137

  Berry, William ^a,b   Friedland, David ^a   Fleagle, John ^a,c   Jackson, Don ^a,d   Ilegbodu, Des ^a   Boehm, Kristi A ^a   Asmar, Lina ^a  

^a Developmental Therapeutics Committee and Co Chair of the Genitourinary Committee   (United States)

^b Cancer Centers of North Carolina   (United States)

^c ROCKY MOUNTAIN CANCER CENTERS   (United States)

^d Asheville Hematology and Oncology Associates PA   (United States)

Author keywords

Adenocarcinoma; Metastasis; Multicenter studies; Progressive disease

Indexed keywords

ANTINEOPLASTIC AGENT; CARBOPLATIN; ESTRAMUSTINE; PACLITAXEL; PROSTATE SPECIFIC ANTIGEN;

ADENOCARCINOMA; AGED; ARTICLE; BLOOD; CLINICAL TRIAL; HUMAN; MALE; MIDDLE AGED; NEOPLASM; PHASE 2 CLINICAL TRIAL; PROSTATE TUMOR; QUALITY OF LIFE; SURVIVAL RATE; TREATMENT OUTCOME;

ADENOCARCINOMA; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARBOPLATIN; ESTRAMUSTINE; HUMANS; MALE; MIDDLE AGED; NEOPLASMS, HORMONE-DEPENDENT; PACLITAXEL; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; QUALITY OF LIFE; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 33846676039     PISSN: 15587673     EISSN: None     Source Type: Journal    
DOI: 10.3816/CGC.2006.n.029     Document Type: Article

References (19)

1. Tannock I. F., Osoba D., Stockler MR, et al. Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-refractory prostate cancer: a Canadian randomized trial with palliative care endpoints. J Clin Oncol 1996; 14:1756-1764.
2. Kantoff PW, Halabi S., Sonaway M., et al. Hydrocortisone with or without mito-xantrone in men with hormone-refractory prostate cancer: results of the Cancer and Leukemia Group B 9182 study. J Clin Oncol 1999; 17:2506-2513.
3. Tannock I. F., de Wit R., Berry WR, et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 2004; 351:1502-1512.
4. Petrylak D. P., Tangen CM, Hussain MH, et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med 2004; 351:1513-1520.
5. Berry WR, Hathorn J. W., Dakhil SR, et al. Phase II randomized trial of weekly paclitaxel with or without estramustine phosphate in metastatic hormone-refractory prostate cancer. Clin Prostate Cancer 2004; 3:104-111.
6. Bubley GI, Carducci M., Dahut W., et al. Eligibility and response guidelines for phase II clinical trials in androgen-independent prostate cancer: recommendations from the Prostate-specific Antigen Working Group. J Clin Oncol 1999; 17:3461-3467.
7. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Soc Assoc 1958; 53:457-481.
8. Hudes G., Einhorn L., Ross E., et al. Vinblastine versus vinblastine plus oral estramustine phosphate for patients with hormone-refractory prostate cancer: a Hoosier Oncology Group and Fox Chase Network phase III trial. J Clin Oncol 1999; 17:3160-3166.
9. Hudes G., Ross E., Roth B., et al. Improved survival for patients with hormone-refractory prostate cancer receiving estramustine-based antimicrotubule therapy: final report of a Hoosier Oncology Group and Fox-Chase Network phase III trial comparing vinblastine and vinbalstine plus oral estramustine phosphate. Proc Am Soc Clin Oncol 2002; 21:177a (Abstract #704).
10. Yagoda A., Watson RC, Natale RB, et al. A critical analysis of response criteria in patients with prostatic cancer treated with cis-diaminedichloride platinum II. Cancer 1979; 44:1553-1562.
11. Miglietta L., Canobio L., Boccardo F. Assessment of response to carboplatin in patients with hormone-refractory prostate cancer: a critical analysis of drug activity. Anticancer Res 1995; 15:2825-2828.
12. Kelly WK, Curley T., Slovin S., et al. Paclitaxel, estramustine phosphate, and carbopla-tin in patients with advanced prostate cancer. J Clin Oncol 2001; 19:44-53.
13. Solit DB, Morris M., Slovin S., et al. Clinical experience with intravenous estramustine phosphate, paclitaxel, and carboplatin in patients with castrate, metastatic prostate adenocarcinoma. Cancer 2003; 98:1842-1848.
14. Urakami S., Igawa M., Kikuno N., et al. Combination chemotherapy with paclitaxel, estramustine and carboplatin for hormone refractory prostate cancer. J Urol 2002; 168:2444-2450.
15. Oh WK, Hagmann E., Manola J., et al. A phase I study of estramustine, weekly docetaxel, and carboplatin chemotherapy in patients with hormone-refractory prostate cancer. Clin Cancer Res 2005; 11:284-289.
16. Oh WK, Halabi S., Kelly WK, et al. A phase II study of estramustine, docetaxel, and carboplatin with granulocyte-colony-stimulating factor support in patients with hormone-refractory prostate cancer: Cancer and Leukemia Group B 99813. Cancer 2003; 98:2592-2598.
17. Oh WK, George DJ, Tay MH. Response to docetaxel/carboplatin in patients with hormone-refractory prostate cancer not responding to taxane-based chemotherapy. Clin Prostate Cancer 2005; 4:61-64.
18. Kelly WK, Scher HI, Mazumdar M., et al. Prostate-specific antigen as a measure of disease outcome in metastatic hormone-refractory prostate cancer. J Clin Oncol 1993; 11:607-615.
19. Verbel DA, Kelly WK, Smaletz O., et al. Estimating survival benefit in castrate meta-static prostate cancer: decision making in proceeding to a definitive phase III trial. Urology 2003; 61:142-144.